Recently, our group reported that prostate cancer patients showed significantly elevated circulating TIMP-1 protein levels compared to men without cancer [155] and that elevated plasma TIMP-1 levels predicted a poor survival in CRPC patients [49,156]. This evidence concerns the gene TIMP1 and prostate cancer.